RxDoctor Payments Data

William Hipps, MD

Ophthalmology · Houston, TXNPI 1891745618

Payments from drug & device makers

$2,623in general payments, 2019–2025

Across 86 payments — averaging $30.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$836
  • Alcon$599
  • Bausch & Lomb Americas Inc.$552
  • Ocular Therapeutix, Inc.$108
  • Novartis$106
  • Dompe US, Inc.$103
  • plus $318 from 11 others

What the payments were for

  • Food & beverage$2,623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,623 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$291,051
Medicare patients
822
Services billed
2,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine228$275,494
LumiganBimatoprost195$124,161
Cyclosporine76$46,003
XiidraLifitegrast23$35,026
CombiganBrimonidine Tartrate/Timolol47$25,203
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol125$22,205
VyzultaLatanoprostene Bunod29$17,463
RhopressaNetarsudil Mesylate22$14,396
Latanoprost1,041$12,058
Prednisolone Acetate297$10,383
MieboPerfluorohexyloctane/Pf12$8,969
Travoprost44$8,435
Ketorolac Tromethamine338$7,543
Brimonidine Tartrate250$6,696
SimbrinzaBrinzolamide/Brimonidine Tart20$5,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$836$424,859470 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$552$61,45764 claims
AlconSimbrinza$599$5,52920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →